Cantargia Publishes Data Validating IL1RAP as a Key PDAC Target
LUND, Sweden, June 27, 2026 Cantargia AB announced the publication of new preclinical and clinical findings in JCI Insight,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LUND, Sweden, June 27, 2026 Cantargia AB announced the publication of new preclinical and clinical findings in JCI Insight,...
AMSTERDAM, The Netherlands – May 6, 2026 Norgine has announced that the Australian Therapeutic Goods Administration (TGA) has granted...
REDWOOD CITY, Calif., December 8, 2025 — Coherus Oncology today announced compelling six-year overall survival (OS) follow-up data from...
